Karus Therapeutics - Articles and news items

Karus Therapeutics doses first lymphoma patients in Phase I KA2237 clinical study

Industry news / 5 October 2016 / Niamh Louise Marriott, Digital Content Producer

KA2237 is a dual-selective inhibitor of two PI3K isoforms, p110β and p110δ. Inhibiting these two isoforms combines an immunotherapeutic response…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+